CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Quercetin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00913081
NCT00913081Phase 4Completed

Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH)

University of Pennsylvania·interventional·Posted Jun 3, 2009·Updated Mar 5, 2015

In Brief

A Phase 4 clinical trial evaluating Quercetin and Placebo for Flushing. Completed, enrolled 17 participants across 2 sites.

Detailed Summary

Niacin, or vitamin B3, is known to improve cholesterol disorders and is the most effective drug to raise HDL, or the "good cholesterol". The use of niacin has been limited because of a peculiar adverse effect referred to as "flushing', which consists of redness, warmth, tingling and burning. A recent animal study suggests that flavonoids may prevent flushing due to niacin better than drugs like aspirin. The ANTI-FLUSH study is being done to assess whether a presently available dietary supplement known as quercetin, which is a flavonoid, can reduce the flushing that occurs with niacin. We will also assess whether using quercetin to prevent flushing from niacin, can improve how niacin lowers cholesterol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFlushing
CountriesUnited States
CollaboratorsAbbott

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 3, 2009
Enrollment StartFeb 1, 2009
Primary CompletionAug 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.1 years ago

Interventions

Quercetindietary

Quercetin 500, 1000, or 2000 mg PO one time

Placebodietary

Placebo PO one time